Abstract
Purpose
This study aimed to determine the possible effects of single-dose intravitreal bevacizumab on nitric oxide (NO) levels in serum and remote organs and to reveal one of the possible mechanisms in the pathophysiology of hypertension.
Methods
Thirty-eight adult New Zealand albino rabbits were divided into a control group (no injection was performed, killed on day 28 of the study), group 1 (killed on day 1 of the study), group 2 (killed on day 7 of the study), group 3 (killed on day 14 of the study), and group 4 (killed on day 28 of the study). The right eyes of the animals in groups 1–4 received an intravitreal single injection of 1.25 mg (0.05 ml) bevacizumab (Avastin), and their brain, heart, liver, kidney, and blood samples were collected. NO levels were evaluated in the serum and organ homogenates. Kidney tissues were assessed by electron microscopy.
Results
Serum, brain, kidney, and liver NO levels significantly decreased in groups 2, 3, and 4 as compared with the control group (P<0.05). In addition, heart NO levels significantly decreased in groups 3 and 4 compared with the control group (P<0.05). There were no electron microscopic changes in the kidneys of either group.
Conclusions
This study demonstrated that single intravitreal injection of bevacizumab decreased NO levels in serum, brain, heart, liver, and kidneys. In addition, there were no electron microscopic changes in the kidneys.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ferrara N . Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581–611.
Shibuya M, Yamaguchi S, Yamane M, Ikeda T, Tojo A, Matsushime H et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519–524.
Terman BI, Dougher VM, Maglione D, Dimitrov D, Armellino DC, Gospodarowicz D et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579–1586.
Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N . Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789–1797.
Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31.
Ferrara N, Hillan KJ, Novotny W . Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328–335.
Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age related macular degeneration. Retina 2006; 26: 383–390.
Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999–1005.
Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695 e1-e15.
Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P . One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009; 247: 27–33.
Arias L, Planas N, Prades S, Caminal JM, Rubio M, Pujol O et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008; 92: 1035–1039.
Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS . Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035–1047.
Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr et al. Short-term safety and efficacy of intravitreal bevacizumab (avastin) for neovascular age related macular degeneration. Retina 2006; 26: 495–511.
Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H . The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye 2009; 23: 1714–1718.
Morbidelli L, Chang CH, Douglas JG, Granger HJ, Ledda F, Ziche M . Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996; 270: H411–H415.
Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM . Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009; 54: 652–658.
Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T . Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94: 1215–1218.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ . Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855–859.
Dinc E, Yildirim O, Yilmaz N, Canacankatan N, Ayaz L, Ozcan T et al. Intravitreal bevacizumab effects on VEGF levels in distant organs: an experimental study. Cutan Ocul Toxicol 2014; 33: 275–282.
Hood JD, Meininger CJ, Ziche M, Granger HJ . VEGF upregulates ecNOS message, protein and NO production in human endothelial cells. Am J Physiol 1998; 274: H1054–H1058.
Wu HM, Huang Q, Yuan Y, Granger HJ . VEGF induces NO-dependent hyperpermeability in coronary venules. Am J Physiol 1996; 271: H2735–H2739.
Kitamoto Y, Tokunaga H, Tomita K . Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest 1997; 99: 2351–2357.
Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605–12608.
Müller-Deile J, Worthmann K, Saleem M, Tossidou I, Haller H, Schiffer M . The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Renal Physiol 2009; 297: F1656–F1667.
Ronco MT, Alvarez Mde L, Monti JA, Carrillo MC, Pisani GB, Lugano MC et al. Role of nitric oxide increase on induced programmed cell death during early stages of rat liver regeneration. Biochim Biophys Acta 2004; 1690: 70–76.
Monacci WT, Merrill MJ, Oldfield EH . Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol 1993; 264: C995–C1002.
Mayhan WG . VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP dependent pathway. Am J Physiol 1996; 276: C1148–C1153.
Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H . Posterior reversible encephalopathy after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy. J Ocul Pharmacol Ther 2010; 26: 301–303.
Matsunaga T, Warltier DC, Weihrauch DW, Moniz M, Tessmer J, Chilian WM . Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 2000; 102: 3098–3103.
Acknowledgements
This study was supported by Mersin University Scientific Research Fund (Grant No: BAP-TF CTB (ED) 2011-3 TU).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Dinc, E., Yildirim, O., Ayaz, L. et al. Effects of intravitreal injection of bevacizumab on nitric oxide levels. Eye 29, 436–442 (2015). https://doi.org/10.1038/eye.2014.297
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2014.297
This article is cited by
-
Changes of plasma nitric oxide, endothelin-1, and blood coagulation following intravitreal conbercept
Scientific Reports (2021)
